Taika Capital’s Biogen BIIB Stock Holding History

Taika Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,305	Closed	-$3.98M	–	50
2023 Q1	$3.98M	Buy	14,305 +7,205	+101%	+$1.99M	1.88%	26
2022 Q4	$1.97M	Hold	7,100	–	–	1.04%	33
2022 Q3	$1.9M	Buy	+7,100	New	+$1.51M	1.16%	34

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Taika Capital's BIIB Position: Q2 2023 in Review

Taika Capital sold out of Biogen (BIIB) in Q2 2023, closing a stake of 14,305 shares — an estimated $3.98M sold.

Taika Capital first reported a position in BIIB in Q3 2022 and held it in 3 quarters. The position peaked at $3.98M in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

Taika Capital reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
Taika Capital sold 14,305 Biogen shares in Q2 2023, an estimated $3.98M.
Taika Capital first reported a position in Biogen in Q3 2022 and held it in 3 quarters.
Taika Capital's Biogen position peaked at $3.98M in Q1 2023.
1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Taika Capital's 13F filing for Q2 2023, filed 14 Aug 2023.